Clinical trials: Trifluridine and Tipiracil
Metastatic Colorectal Cancer
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Thalidomide has both anti-angiogenesis and antiemetic effects, and its combined use with TAS-102 may reduce the gastrointestinal reactions associated with TAS-102, while enhancing antitumor efficacy and reducing the side effects…
- Trial name
- NCT05266820
- Testing
- Thalidomide, TAS-102
- Where
- 6 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer Metastatic
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF…
- Trial name
- NCT06379399
- Testing
- Cetuximab, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Wangxia LV
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7
TAS-102 in Treating Advanced Biliary Tract Cancers
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body.
- Conditions
- Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7
- Trial name
- NCT03278106
- Testing
- Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Colorectal Cancer (CRC)
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and…
- Trial name
- CodeBreak300 (NCT05198934)
- Testing
- Sotorasib, Panitumumab, Trifluridine and Tipiracil
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Metastatic Oesogastric Adenocarcinoma
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
Advanced cancer of the stomach and the gastro-esophageal junction (G/GEJ) remains a very serious disease. Today, only about 10-15% of patients are alive after 5 years.
- Trial name
- FRUQUITAS (NCT07270991)
- Testing
- trifluridine/tipiracil, fruquintinib
- Where
- 64 sites in France, Germany
- Volunteers
- 324 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This study will evaluate the safety and feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102) and Oxaliplatin (iTTo) for treatment naïve advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT04808791
- Testing
- Irinotecan, Oxaliplatin, TAS 102 (Trifluridine/Tipiracil)
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- AHS Cancer Control Alberta
Metastatic Colorectal Cancer
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
Prospective cohort of patients treated with trifluridine/tipiracil, maximal sample size 250 patients. It is expected, that 89 patients will experience a grade 3-4 neutropenia and will be included in the phase II.
- Trial name
- LONGBOARD (NCT04166604)
- Testing
- Trifluridine/Tipiracil
- Where
- 22 sites in France
- Volunteers
- 176 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared…
- Trial name
- AndroMETa-CRC (NCT07525206)
- Testing
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 990 people
- Sponsor
- AbbVie
Locally Advanced Rectal Cancer
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with…
- Trial name
- NCT04177602
- Testing
- Trifluridine/tipiracil chemoradiation, Capecitabine based chemoradiation
- Where
- 8 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
In mCRC, response to second-line chemotherapy is limited, and few treatment options are available. It is urgent to design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients…
- Trial name
- NCT06202001
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer (GC)
A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy
This study aims to evaluate the efficacy and safety of TAS-102 combined with nedaplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma who have experienced disease progression after two or more…
- Trial name
- NCT07913165
- Testing
- TAS102+Nedaplatin
- Volunteers
- 36 people
- Sponsor
- Tao Zhang